| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2124579 | European Journal of Cancer | 2009 | 5 Pages |
Abstract
These results show that ifosfamide is associated with a lower risk of gonadal damage than cyclophosphamide. The risk of abnormal FSH increased with the cumulative dose of cyclophosphamide.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vita Ridola, Oumaya Fawaz, Françoise Aubier, Christophe Bergeron, Florent de Vathaire, Fabienne Pichon, Daniel Orbach, Jean Claude Gentet, Claudine Schmitt, Christelle Dufour, Odile Oberlin,